After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more

StreetInsider2021-11-17

After-Hours Stock Movers:

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.

Chembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.

StoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.

Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.

La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.

Varex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.

ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.

EyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.

Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

SamYYL
2021-11-17
SamYYL
Like
- sugizoi4u:
  Done
Dennyeo
2021-11-17
Dennyeo
Yeah
JDomXYZi
2021-11-17
JDomXYZi
Please like!
- Dennyeo:
  Kok
hiryan
2021-11-17
hiryan
Hi
- JDomXYZi:
  hi
wakalah
2021-11-17
wakalah
Like please
- qiqi2:
  K
- Txfen80:
  Ok
shamtu
2021-11-17
shamtu
Like

发表看法

347

787

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2184884068?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-17 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2184884068","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","media":"StreetInsider","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","article_id":"2184884068","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","pubTimestamp":1637105747,"columns":[],"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"translate_title":"盘后股票搬运工：Atea制药、Chembio诊断等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9},"content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":878030747,"gmtCreate":1637120951030,"gmtModify":1637120952006,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878030747","repostId":2184884068,"repostType":4,"repost":{"id":"2184884068","kind":"news","pubTimestamp":1637105747,"share":"https://ttm.financial/m/news/2184884068?lang=&edition=full","pubTime":"2021-11-17 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","media":"StreetInsider","summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184884068","content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","news_type":1,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6610758,"gmtCreate":1637121515628,"gmtModify":1637121515663,"authorId":3580348004146675,"author":{"id":3580348004146675,"idStr":"3580348004146675","authorId":3580348004146675,"name":"sugizoi4u","avatar":"https://static.tigerbbs.com/c7f987f771f67981d200c8f1cd598c70","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878030747,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":878096190,"gmtCreate":1637120196982,"gmtModify":1637120197608,"author":{"id":"3582021832486442","authorId":"3582021832486442","name":"Dennyeo","avatar":"https://static.tigerbbs.com/25b7d84fd64f134409a4350c85c88965","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582021832486442","authorIdStr":"3582021832486442"},"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878096190","repostId":2184884068,"repostType":4,"repost":{"id":"2184884068","kind":"news","pubTimestamp":1637105747,"share":"https://ttm.financial/m/news/2184884068?lang=&edition=full","pubTime":"2021-11-17 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","media":"StreetInsider","summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184884068","content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","news_type":1,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":878098547,"gmtCreate":1637120111932,"gmtModify":1637120112142,"author":{"id":"3578006677235346","authorId":"3578006677235346","name":"JDomXYZi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3578006677235346","authorIdStr":"3578006677235346"},"htmlText":"Please like!","listText":"Please like!","text":"Please like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878098547","repostId":2184884068,"repostType":4,"repost":{"id":"2184884068","kind":"news","pubTimestamp":1637105747,"share":"https://ttm.financial/m/news/2184884068?lang=&edition=full","pubTime":"2021-11-17 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","media":"StreetInsider","summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184884068","content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","news_type":1,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6610556,"gmtCreate":1637120220232,"gmtModify":1637120220266,"authorId":3582021832486442,"author":{"id":3582021832486442,"idStr":"3582021832486442","authorId":3582021832486442,"name":"Dennyeo","avatar":"https://static.tigerbbs.com/25b7d84fd64f134409a4350c85c88965","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878098547,"type":1,"supId":0,"prevId":0,"content":"Kok","text":"Kok","html":"Kok"}],"langContent":"CN"},{"id":878098301,"gmtCreate":1637120059461,"gmtModify":1637120059633,"author":{"id":"3566188406021924","authorId":"3566188406021924","name":"hiryan","avatar":"https://static.tigerbbs.com/b6d871adf76ee05a7b420452b564855f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566188406021924","authorIdStr":"3566188406021924"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878098301","repostId":2184884068,"repostType":4,"repost":{"id":"2184884068","kind":"news","pubTimestamp":1637105747,"share":"https://ttm.financial/m/news/2184884068?lang=&edition=full","pubTime":"2021-11-17 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","media":"StreetInsider","summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184884068","content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","news_type":1,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6610544,"gmtCreate":1637120103507,"gmtModify":1637120103604,"authorId":3578006677235346,"author":{"id":3578006677235346,"idStr":"3578006677235346","authorId":3578006677235346,"name":"JDomXYZi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878098301,"type":1,"supId":0,"prevId":0,"content":"<u>hi</u>","text":"<u>hi</u>","html":"<u>hi</u>"}],"langContent":"CN"},{"id":878091639,"gmtCreate":1637119973956,"gmtModify":1637119974137,"author":{"id":"4099452516805430","authorId":"4099452516805430","name":"wakalah","avatar":"https://static.tigerbbs.com/e394bc54c2348db567055b8aae79949d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4099452516805430","authorIdStr":"4099452516805430"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878091639","repostId":2184884068,"repostType":4,"repost":{"id":"2184884068","kind":"news","pubTimestamp":1637105747,"share":"https://ttm.financial/m/news/2184884068?lang=&edition=full","pubTime":"2021-11-17 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","media":"StreetInsider","summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184884068","content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","news_type":1,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6610562,"gmtCreate":1637120259768,"gmtModify":1637120259874,"authorId":3573803041677956,"author":{"id":3573803041677956,"idStr":"3573803041677956","authorId":3573803041677956,"name":"qiqi2","avatar":"https://static.tigerbbs.com/836c56071da9ab9941909ee1186113fe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878091639,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"},{"id":6610535,"gmtCreate":1637120077100,"gmtModify":1637120077187,"authorId":3586489129629376,"author":{"id":3586489129629376,"idStr":"3586489129629376","authorId":3586489129629376,"name":"Txfen80","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":878091639,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":878091960,"gmtCreate":1637119911694,"gmtModify":1637119912861,"author":{"id":"3582095823167500","authorId":"3582095823167500","name":"shamtu","avatar":"https://static.tigerbbs.com/924aa8f9aefe409906eeee3a22eb49b8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582095823167500","authorIdStr":"3582095823167500"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878091960","repostId":2184884068,"repostType":4,"repost":{"id":"2184884068","kind":"news","pubTimestamp":1637105747,"share":"https://ttm.financial/m/news/2184884068?lang=&edition=full","pubTime":"2021-11-17 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2184884068","media":"StreetInsider","summary":"$Atea Pharmaceuticals, Inc.$  9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.$Chembio Diagnostics$, Inc.  8.7% HIGHER; announced the su","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/AVIR\">Atea Pharmaceuticals, Inc.</a> (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.</p>\n<p><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.</p>\n<p><a href=\"https://laohu8.com/S/STNE\">StoneCo</a> (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.</p>\n<p>Dolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.</p>\n<p>La-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.</p>\n<p><a href=\"https://laohu8.com/S/VREX\">Varex Imaging Corporation</a> (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.</p>\n<p>ViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.</p>\n<p><a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.</p>\n<p>Nikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Atea Pharmaceuticals, Chembio Diagnostics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19229173><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19229173\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4198":"医疗保健用品","DLB":"杜比","BK4516":"特朗普概念","BK4106":"数据处理与外包服务","BK4097":"系统软件","VREX":"Varex Imaging Corporation","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4095":"家庭装饰品","LZB":"La-Z-Boy家具","CEMI":"Chembio Diagnostics","BK4007":"制药","STNE":"StoneCo","BK4559":"巴菲特持仓","AVIR":"Atea Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19229173","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184884068","content_text":"After-Hours Stock Movers:\nAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.\nChembio Diagnostics, Inc. (Nasdaq: CEMI) 8.7% HIGHER; announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.\nStoneCo (NASDAQ: STNE) 8.4% LOWER; reported Q3 EPS of R$0.46, versus R$0.99 reported last year. Revenue for the quarter came in at R$1.47 billion, versus R$934.3 million reported last year.\nDolby Laboratories (NYSE: DLB) 7% LOWER; reported Q4 EPS of $0.58, $0.02 better than the analyst estimate of $0.56. Revenue for the quarter came in at $285 million versus the consensus estimate of $299.95 million. Dolby Laboratories sees Q1 2022 EPS of $0.98-$1.13, versus the consensus of $1.31. Dolby Laboratories sees Q1 2022 revenue of $345-375 million, versus the consensus of $389 million. Dolby Laboratories sees FY2022 EPS of $3.52-$4.02, versus the consensus of $3.94. Dolby Laboratories sees FY2022 revenue of $1.34-1.4 million, versus the consensus of $1.37 million.\nLa-Z-Boy (NYSE: LZB) 7% HIGHER; reported Q2 EPS of $0.85, $0.12 better than the analyst estimate of $0.73. Revenue for the quarter came in at $576 million versus the consensus estimate of $540.04 million.\nVarex Imaging Corporation (NASDAQ: VREX) 6.2% HIGHER; reported Q4 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $226 million versus the consensus estimate of $215.5 million. Varex Imaging Corporation sees Q1 2022 EPS of $0.20-$0.40, versus the consensus of $0.22. Varex Imaging Corporation sees Q1 2022 revenue of $200-220 million, versus the consensus of $192.2 million.\nViewRay, Inc. (Nasdaq: VRAY) 4.7% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commission.\nEyePoint (NASDAQ: EYPT) 4.3% LOWER; announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.\nNikola (NASDAQ: NKLA) 1.6% LOWER; Files to Offer 29M Shares for Tumim Stone Capital","news_type":1,"symbols_score_info":{"AVIR":0.9,"CEMI":0.9,"DLB":0.9,"LZB":0.9,"STNE":0.9,"VREX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":787,"commentSize":347,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.2","shortVersion":"4.34.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2184884068"}